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Described herein are improved electrode array devices and 
improved active agent delivery devices. Further described are 
methods of making and using the improved devices. An 
improved electrode array device includes a substrate and a 
plurality of probes disposed on the substrate, wherein the 
probes are formed from a plurality of aligned carbon nano-
tubes that are not encapsulated by a structure-providing mate-
rial. An active agent delivery device includes a substrate 
having an aperture therein, an active agent delivery member 
disposed on a first surface of the substrate and having an 
aperture therein, and an active agent chamber disposed on a 
second surface of the substrate configured to deliver an active 
agent through the aperture of the substrate and the aperture of 
the active agent delivery member. 
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ELECTRODE ARRAYS AND METHODS OF 
MAKING AND USING SAME 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a United States National Stage Appli-
cation of International Patent Application Ser. No. PCT/ 
US2009/038849, filed 30 Mar. 2009, and entitled "Electrode 
Arrays and Methods of Making and Using Same," which 
claimed the benefit of U.S. Provisional Patent Application 
Ser. No. 61/040,365, filed 28 Mar. 2008, which are incorpo-
rated herein by reference in their entireties as if fully set forth 
below. 
TECHNICAL FIELD 
The various embodiments of the present invention relate 
generally to electrode arrays, and more particularly, to carbon 
nanotube-containing electrode arrays, and to methods of 
making and using such devices. 
BACKGROUND 
Electrode arrays, having a plurality of electrode probes or 
shanks, are widely used in biological applications, for 
example, to stimulate and/or record electrical activity in cells 
2 
It is to the provision of such electrode array devices that 
some of the various embodiments of the present invention are 
directed. 
BRIEF SUMMARY 
The various embodiments of the present invention provide 
improved electrode array devices, improved active agent 
delivery devices, and methods of making and using such 
10 devices. 
An electrode array device according to some embodiments 
of the present invention includes a substrate and a plurality of 
probes disposed on the substrate. Each probe of the plurality 
of probes can include a plurality ofaligned carbon nanotubes. 
15 The plurality of aligned carbon nanotubes are not encapsu-
lated by a structure-providing material, such as a polymeric 
matrix. 
The electrode array device can also include a plurality of 
electrical contacts. Each electrical contact can be disposed 
20 between a probe and the substrate. The electrode array device 
can also include a processing component that is in electrical 
communication with at least one of the probes. 
In some situations, each probe is electrically isolated from 
one another. The carbon nanotubes or each probe can be 
25 functionalized to increase the density of the carbonnanotubes 
within that probe. For example, the carbon nanotubes can be 
functionalized with poly-L-lysine. Alternatively, the carbon 
nanotubes can be functionalized with a laminin. 
or tissues. By way of illustration, when the cells in nervous 
tissue (i.e., neurons and neuroglia) or muscle tissue (i.e., 30 
muscle cells) are excited, a current is generated. This current 
results in a change in voltage both inside and outside of the 
cells. Thus, an electrode array can be used to monitor the 
changes in voltage and/or to provide a voltage stimulus for the 
purposes of research, diagnosis, treatment or therapy, and the 35 
like. 
According to other embodiments of the present invention, 
an electrode array device includes a substrate and a plurality 
of probes disposed on the substrate. In some cases, each probe 
of the plurality of probes consists of a plurality of vertically 
aligned carbon nanotubes. 
According to some embodiments of the present invention, 
an active agent delivery device can include a substrate having 
an aperture therein and an active agent delivery member 
disposed on a surface of the substrate and having an aperture 
therein. The active agent delivery member can be formed 
from a plurality of aligned carbon nanotubes. The aperture of 
40 the active agent delivery member and the aperture of the 
substrate can be substantially coaxial. The active agent deliv-
ery device can also include means for delivering an active 
agent through the aperture of the substrate and the aperture of 
Many electrode array devices suffer from poor biocompat-
ibility. As part of the body's immunological response to a 
recognized foreign body, implanted electrode array devices 
can experience a biofouling process in which local cells sur-
round the probes of the electrode array device and ultimately 
wall off the implanted device from the body. For example, 
within hours of implantation of an electrode array device for 
neural studies, an increased population of astrocytes and glial 45 
cells can surround the individual probes of the array. These 
microglia can then initiate inflammation, and the process of 
phagocytosis of the foreign material begins. Over time, the 
astrocytes and microglia begin to accumulate, forming a 
sheath surrounding the probes of the electrode array that 
extends tens of micrometers around the device. 
the active agent delivery member. 
An active agent delivery device, according to other 
embodiments of the present invention, can include a substrate 
having an aperture therein and an active agent delivery mem-
ber disposed on a first surface of the substrate. The active 
agent delivery member can have an aperture therein. The 
50 active agent delivery member can be formed from a plurality 
of aligned carbon nanotubes. The aperture of the active agent 
delivery member and the aperture of the substrate can be 
substantially coaxial. The active agent delivery device can 
also include an active agent chamber disposed on a second 
As a result of such inflammation and biofouling processes, 
electrode array devices often must be removed and the same 
(or another) array must be implanted in another location. This 
cycle of chronic implantation and removal can result in 
inflammation, cell loss, scar tissue formation, and the like. 
Continuing the example of the electrode array device for 
neural studies described above, chronic implantation and 
removal of such devices has been shown to lead to neuron 
55 surface of the substrate. The active agent chamber can be 
configured to deliver an active agent through the aperture of 
the substrate and the aperture of the active agent delivery 
member. 
loss, axon length reduction, neurodegeneration, and glial 60 
The active agent delivery device can include a processing 
component in electrical communication with the active agent 
chamber and/or the active agent delivery member. scarring. 
Accordingly, there remains a need for improved electrode 
array devices for biological applications. It would be particu-
larly advantageous if the improved devices reduced or elimi-
nated adverse immunological reactions thereto. Such 
improved electrode array devices would be more effective 
and have longer service lifetimes. 
The active agent delivery device can also include an elec-
trical contact that is disposed between at least a portion of the 
active agent delivery member and at least a portion of the 
65 substrate. 
Yet another active agent delivery device can include a 
substrate having a plurality of apertures therein and a plurality 
US 8,774,890 B2 
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of active agent delivery members disposed on a first surface of 
the substrate. Each active agent delivery member of the plu-
rality of active agent delivery members can have an aperture 
therein. Each active agent delivery member of the plurality of 
active agent delivery members can include a plurality of 
aligned carbon nanotubes. Each aperture of an active agent 
delivery member can be substantially coaxial with an aperture 
of the substrate. The active agent delivery device can further 
include an active agent chamber disposed on a second surface 
of the substrate configured to deliver an active agent through 10 
at least one aperture of the substrate and at least one active 
agent delivery member aperture. 
Other aspects and features of embodiments of the present 
invention will become apparent to those of ordinary skill in 
the art, upon reviewing the following detailed description in 15 
conjunction with the accompanying figures. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic illustration of a carbon nanotube- 20 
containing electrode array device in accordance with some 
embodiments of the present invention. 
4 
are used to distinguish one element from another. Further, the 
terms "a", "an", and "the" do not denote a limitation of 
quantity, but rather denote the presence of"at least one" of the 
referenced item. 
As stated above, various embodiments of the present inven-
tion are directed to improved electrode array devices. The 
improved electrode array devices described herein are so-
called "microelectrode arrays." Other embodiments of the 
present invention are directed to improved active agent deliv-
ery devices. The electrode array devices and active agent 
delivery devices are beneficial because their pro bes and active 
agent deliver members, respectively, are of such a small size 
that the body either does not recognize them as a foreign 
object to which an immunological response is necessary or 
has a delayed response to them. The improved devices 
described herein make use of a plurality of vertically aligned 
carbonnanotubes (CNTs) as the probes or active agent deliv-
ery members, as will be described in more detail below. 
As used herein, the term "aligned" encompasses items 
having at least a portion of a dimension (e.g., length, width, 
height, or the like) being either parallel to each otheror within 
about 15 degrees of being parallel to one another if projected 
infinitely into space. Thus, two CNTs that do not directly 
FIG. 2 is a schematic illustration of a carbon nanotube-
containing electrode array device in accordance with other 
embodiments of the present invention. 
FIG. 3 is a schematic illustration of a carbon nanotube-
containing active agent delivery device in accordance with 
some embodiments of the present invention. 
FIG. 4 is a schematic illustration of a carbon nanotube-
containing active agent delivery device in accordance with 
other embodiments of the present invention. 
25 contact each other, but would contact each other if the CNTs 
were infinitely long, and the angle formed between them is 
less than or equal to about 15 degrees, are considered aligned 
for the purposes of this disclosure. When a number of items 
are described herein as being aligned, then at least 70 percent 
FIG. 5 is a scarming electron microscope image of an array 
of carbon nanotube electrodes in accordance with the data in 
EXAMPLE 1. 
30 of the items are aligned with one another. Thus, in referring to 
a plurality ofCNTs being vertically aligned, it is intended that 
at least a portion of the length (i.e., the axis perpendicular to 
the diameter of the CNT) of at least 70 percent of the CNTs in 
FIG. 6(a) is a scanning electron microscope image of an 35 
array of carbon nanotube electrodes, after implantation, in 
accordance with the data in EXAMPLE 2. 
FIG. 6(b) is a scanning electron microscope image of a 
carbon nanotube electrode, after implantation, in accordance 
with the data in EXAMPLE 2. 
FIG. 7 is a scarming electron microscope image of an array 
of functionalized carbon nanotube electrodes, after implan-
tation, in accordance with the data in EXAMPLE 2. 
40 
the plurality are aligned. For example, when a plurality of 
vertically aligned CNTs are not linear and/or bundle together 
to form so-called "ropes," then a portion of the lengths (or the 
entire lengths) of at least 70 percent of the CNTs are either 
parallel or within about 15 degrees of being parallel to one 
another. 
A cross-section of an electrode array device, according to 
some embodiments of the present invention, is shown in FIG. 
1. The electrode array device, which is designated by refer-
ence numeral 100, generally includes a substrate 102 and a 
plurality of probes or shanks 104 disposed on at least a portion FIG. 8 is a scarming electron microscope image of an array 
of functionalized carbon nanotube electrodes showing cell 
growth in accordance with the data in EXAMPLE 2. 
45 of the substrate 102. 
FIG. 9(a) is a scanning electron microscope image of an 
aperture in a silicon wafer in accordance with the data in 
EXAMPLE3. 
FIG. 9(b) is a scanning electron microscope image of a 50 
carbon nanotube-containing active agent delivery member in 
accordance with the data in EXAMPLE 3. 
DETAILED DESCRIPTION 
Within the electrode array device 100, there is no limitation 
on the composition or material from which the substrate 102 
is formed. When the plurality of probes 104 are intended to be 
electrically isolated from one another so as to provide each 
probe 104 with the ability to discretely measure and/or stimu-
late a specific location of the bio-environment in which the 
electrode array device 100 is implanted for in vivo applica-
tions (or to which the electrode array device 100 is contacted 
for in vitro applications), the substrate 102 must be formed 
Referring now to the figures, wherein like reference numer-
als represent like parts throughout the several views, exem-
plary embodiments of the present invention will be described 
55 from an insulating or dielectric material. This is to prevent the 
possibility of a short circuit between individual probes 104 of 
the electrode array device 100. 
If the plurality of probes 104 are designed to provide a 
uniform stimulus and/or to take a single measurement across 
60 the entire electrode array device, then the substrate 102 does 
not need to be formed from an insulating material. This con-
figuration will be described in more detail with reference to 
FIG. 2 below. 
in detail. Throughout this description, various components 
may be identified having specific values or parameters, how-
ever, these items are provided as exemplary embodiments. 
Indeed, the exemplary embodiments do not limit the various 
aspects and concepts of the present invention as many com-
parable parameters, sizes, ranges, and/or values may be 
implemented. The terms "first," "second," "primary," "sec- 65 
ondary," "top," "bottom," "distal," "proximal," and the like, 
do not denote any order, quantity, or importance, but rather 
Each probe 104 of the plurality of probes comprises a 
plurality of vertically aligned CNTs that project away from 
the substrate 102. The probes 104 can be directly or indirectly 
(i.e., via an intermediate layer of material) connected to the 
US 8,774,890 B2 
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substrate 102. In addition, the probes 104 can be oriented 
perpendicular to, or slanted at any angle with respect to, the 
substrate 102. 
The CNTs that are used to make the probes 104 of the 
electrode array device 100 can be any type of carbon nano-
tube, including single wall nanotubes (SWNTs), multi-wall 
carbon nanotubes (MWNTs ), or a combination of both types 
of carbon nanotubes. Additional details regarding the CNTs 
will be provided below in describing the manufacture of the 
electrode array device 100. 
There is no particular limitation on the shape of the probes 
104. The probes 104 can be identical to one another, or can 
have different shapes. Thus, the plurality of vertically aligned 
CNTs of a probe 104 can have the shape of a circle, triangle, 
square, rectangle, pentagon, a cross, a star, a torus or donut, 
any other polygon whether solid or hollow (e.g., like donut), 
or any other shape. 
There is no particular limitation on the height of the CNTs 
of the probes 104. The probes 104 can have identical heights, 
6 
nological response is not triggered. Otherwise, there is no 
limitation on the number and spacing of probes 104 on a 
particular substrate 102. 
The electrode array device 100 can further include an (i.e., 
at least one) optional processing component or unit 108. The 
optional processing component 108 is configured to record 
any voltage changes detected by the individual probes 104 
and/or provide stimulus voltages to the individual probes 104. 
The processing component 108 can include a voltage source, 
10 an amplifier, a multi-channel switch, a computing device, 
signal processing circuitry, signal processing software or 
algorithms, or combinations of two or more of the foregoing. 
The individual devices of the processing component 108 and 
the arrangement thereof will be understood by those skilled in 
15 the art to which this disclosure pertains. 
Because the plurality of probes 104 in the electrode array 
device 100 of FIG. 1 are electrically isolated from one 
another, each of the probes 104 independently must be in 
electrical communication with the processing component 
20 108. 
or they can have different heights. For example, it may desir-
able to have probes 104 of different heights so that each probe 
104 can measure electrical activity or stimulate not only 
different lateral areas but different depths within the bio-
environment in which the electrode array device 100 is 25 
implanted for in vivo applications (or to which the electrode 
array device 100 is contacted for in vitro applications). 
In order for each probe 104 to be electrically isolated from 
one another, the electrode array device 100 must have an 
electrical contact 106 for each probe 104. The electrical con-
tact 106 can be a conducting layer interposed between the 
substrate 102 and the probe 104. 
During operation of the electrode array device 100, the 
electrode array device 100 is implanted in, or contacted with, 
the bio-environment of interest. For illustrative convenience 
only, and with no intention to be limited thereto, reference 
will be made to nervous tissue or muscle tissue as the bio-
environment of interest. When the electrode array device 100 
When the pressure necessary to penetrate into a particular 
type of tissue is high, the CNTs can be arranged to provide the 
probes 104 with a quality of"sharpness." That is, there can be 30 
a gradient in the height of the CNTs such that those in the 
center of the plurality of vertically aligned CNTs are taller 
than those at the periphery of the plurality of vertically 
aligned CNTs so as to mimic the tip of a sharp pencil. In other 35 
situations, the gradient in the height of the CNTs can be 
created to provide a saw-toothed or serrated profile. Alterna-
tively, the overall shape of the probes 104 can be used to 
provide similar features. For example, the CNTs can be 
arranged to have a star-shape, wherein the CNTs of each side 40 
or leg of the star have a gradient in the height of the CNTs such 
that those in the center of the side or leg are taller than those 
at the periphery of the side or leg of the star. Other arrange-
ments of the CNTs in each probe 104 can be created to 
provide a quality of sharpness as will be understood by those 45 
skilled in the art to which this disclosure pertains. 
is used to measure electrical activity, each individual probe 
104 will transduce any change in voltage from the muscle 
tissue or nervous tissue environment (e.g., a twitch in muscle 
cells, an action potential in neurons, or the like) caused by ion 
conduction into an electric current. These electric currents are 
then measured by the processing component 106 for subse-
quent processing or analysis. When the electrode array device 
100 is used to provide electrical activity for stimulation, the 
processing component 106 will provide an electric current to 
a specific probe(s) 104. The probe 104 will transduce the 
electric current into an ionic current through the muscle or 
nervous tissue. The ionic current then triggers the voltage-
gated ion charmels on the membranes of the excitable cells, 
causing the cells to depolarize and trigger either an action 
potential if it a nervous cell or a twitch if it is a muscle cell. 
An advantage of using a plurality of vertically aligned 
CNTs as a probe 104 forthe electrode array device 100 is that 
the probes 104 can have dimensions that are significantly 
The longest lateral cross-sectional dimension of the probes 
104 is less than about 50 micrometers. As used herein "lateral 
cross-sectional dimension" refers to a particular dimension of 
a probe 104 that is parallel to the surface of the substrate 102. 
Thus, to clarify, when a probe 104 is circular, the longest 
lateral cross-sectional dimension is its diameter; when a 
probe 104 is square-shaped, the longest lateral cross-sec-
tional dimension is the diagonal between two opposite cor-
ners; and when a probe 104 is star-shaped, the longest lateral 
cross-sectional dimension is the line between any two oppos-
ing legs or sides of the star. Without intending to be bound by 
theory, it is believed that the body does not recognize or has 
difficulty recognizing foreign objects that are smaller than 
about 50 micrometers. Thus, because the probes 104 have 
dimensions that are smaller than this threshold size, they are 
less likely to be susceptible to any biofouling or otherwise 
adverse reactions. 
50 smaller than existing electrode array devices. The high con-
ductivity of CNTs allows for greater sensitivity than other 
probe compositions; and the high Young's modulus of the 
CNTs allows for greater mechanical stability than other probe 
compositions.As a result, the probes 104 can be made to have 
The minimum spacing between individual probes 104 
should be sufficiently large that electrical isolation can be 
maintained therebetween. Also, the probes 104 should be 
sufficiently far apart from one another that the body's immu-
55 significantly smaller lateral cross-sectional dimensions and 
shorter lengths. For example, in some cases, the probes 104 
have longest lateral cross-sectional dimensions that are less 
than or equal to about 20 micrometers. In certain cases, these 
dimensions can be less than or equal to about 10 micrometers. 
60 In situations where greater sensitivity is required, larger 
probes should be selected. 
Another advantage of using a plurality of vertically aligned 
CNTs as a probe 104 forthe electrode array device 100 is that 
the electrical activity is not measured or stimulated from any 
65 one point, but is spread across many single nanotubes. Thus, 
in contrast to existing electrode array devices where a probe 
consists of a single element or member, a probe 104 within the 
US 8,774,890 B2 
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electrode array device 100 of the present invention does not 
fail simply because a single CNT fails (e.g., because ofbio-
fouling, improper positioning, or the like) to measure or 
stimulate electrical activity. 
8 
CNTs can also be dried. Similarly, procedures for drying 
CNTs (while on the electrical contacts 106) are well known to 
those skilled in the art to which this disclosure pertains. 
Depending on the particular application for the electrode 
array device 100 formed therefrom, the CNTs can be option-
ally derivatized on their ends and/or sides with a functional 
group. These functional groups can include an alkyl; acyl; 
aryl; aralkyl; halogen; substituted or unsubstituted thiol; sub-
stituted or unsubstituted amino; hydroxyl; an OR' wherein R' 
A process for making the electrode array device 100 
includes first providing a substrate 102 on which the probes 
104 can be disposed. Next, the electrical contacts 106 can be 
disposed on the substrate 102. This can be accomplished 
using any known technique for doing so. For example, the 
electrical contacts 106 can be pre-fabricated, and can be fas-
tened (e.g., mechanically or chemically) to the substrate 102. 
Alternatively, the electrical contacts 106 can be fabricated 
directly on the substrate 102 using any known fabrication 
technique. Examples of such techniques include physical 
vapor deposition and all of the variants thereof, chemical 
vapor deposition and all of the variants thereof, electro less or 
electrolytic plating, wet chemical methods (e.g., sol-gel, 
chemical surface modifications, or other like method), sput-
tering and all of the variants thereof, ablation deposition and 
all of the variants thereof, molecular beam epitaxy and all of 
the variants thereof, photo lithography, thermal surface modi-
fications, and the like. 
10 can include an alkyl, acyl, aryl, aralkyl, substituted or unsub-
stituted amino, substituted or unsubstituted thiol, and halo-
gen; a linear or cyclic carbon chain optionally interrupted 
with one or more heteroatom, and optionally substituted with 
one or more =0, or=S, hydroxyl, aminoalkyl group, amino 
15 acid, or a peptide; an amino acid (e.g., lysine, L-lysine, or 
modified lysine) or polymer thereof; or a laminin or polymer 
thereof. The extent of the substitution can be tailored to 
achieve the desired electronic or chemical effect, as would be 
understood to those skilled in the art to which this disclosure 
20 pertains. By way of one example, the number of carbon atoms 
in the alkyl, acyl, aryl, aralkyl groups can be in the range of 1 
to about 30. 
Also depending on the particular application for the elec-
trode array device 100, the CNTs can be optionally treated 
(e.g., with an acid or other chemical) so as to alter their 
lengths. 
Mechanisms for rendering the electrical contacts 106 in 
electrical communication with the processing component 
108 can be implemented. For example, individual electrical 25 
leads are coupled to the electrical contacts 106. The electrical 
leads can be disposed on the substrate, through the substrate, After the CNTs have been disposed on the electrical con-
tacts 106, the optional processing component 108 can be 
connected to the appropriate leads. The electrode 100 is then 
30 complete and is ready for use. 
or the like. This can be accomplished using any known fab-
rication technique either before, after, or at the same time the 
electrical contacts 106 are disposed on the substrate. 
After the electrical contacts 106 have been disposed on the 
substrate 102, the pluralities of vertically aligned CNTs can 
be created on the electrical contacts 106. 
Once again, the CNTs that are used to make the probes 104 
of the electrode array device 100 can be any type of carbon 35 
nanotube, including SWNTs, MWNTs, or a combination of 
both types of carbon nanotubes. The CNTs can be made from 
any known means, including, but not limited to, chemical 
vapor deposition and all of its variations (e.g., catalytic 
chemical vapor deposition using carbon-containing feed- 40 
stocks and/or metal catalyst particles, plasma-enhanced 
chemical vapor deposition, thermally-enhanced chemical 
vapor deposition, and the like) or any other method for syn-
thesizing carbon nanotubes on a surface. 
The CNTs can also optionally include non-carbon ele- 45 
ments in the backbone. For example, elements such as boron, 
nitrogen, sulfur, silicon, or the like, can be included in the 
backbone of the CNTs depending on the particular applica-
tion for the electrode array device 100 formed therefrom. 
The average diameterofthe CNTs can be about 0.5 nanom- 50 
eters (nm) to about 75 nm. In some situations, it is desirable to 
use nanotubes having an average diameter of less than or 
equal to about 10 nm. The average length of the nanotubes can 
be greater than or equal to about 10 nm. For example, nano-
tubes having lengths on the order of millimeters or even 55 
centimeters could be used. In certain situations, however, the 
height of the nanotubes is less than about 50 micrometers. 
It is desirable for the CNTs to have a purity of at least 95 
percent(%), and preferably at least 99%, in order to minimize 
the potential for adverse affects caused by impurities within 60 
the CNT sample. Thus, the CNTs can optionally be purified to 
remove non-nanotube carbon, such as amorphous carbon, 
and metallic catalyst residues. 
Purification can be achieved by any known means. Proce-
dures for purification of carbon nanotubes (while on the elec- 65 
trical contacts 106) are well known to those skilled in the art 
to which this disclosure pertains. The optionally purified 
By way of example, one process for preparing an electrode 
array device 100 involves first providing a silicon wafer as the 
substrate 102. A thin film ofSi02 , which serves to renderthe 
substrate an insulator, is thermally grown on the top side of 
the substrate 102. The top surface of the substrate 102 (i.e., the 
one containing the Si02 film) is then patterned with a photo-
resist using photolithography. The pattern corresponds to the 
locations of the pluralities of the electrical contacts 106 and, 
optionally, the electrical leads for coupling the electrical con-
tacts 106 with the processing component 108. 
A thin layer of chromium (Cr), copper (Cu), or other con-
ductive material is subsequently deposited on the substrate 
102 by electron beam evaporation. The portions of the thin 
film that are directly in contact with the substrate 102 act as 
the electrical contacts 106 and, optionally, the electrical leads. 
If the electrical leads are indeed made in this fashion, they are 
then patterned with a photoresist using photo lithography. The 
apertures in this pattern correspond only to the locations of 
the pluralities of CNTs to be grown (which are directly on at 
least a portion of the electrical contacts 106). 
The apertures allow for a line-of-sight deposition path for 
the deposition of an iron (Fe) catalyst layer directly on the 
electrical contacts 106. This will ensure that an ohmic con-
nection exists between the probes 104 and the electrical con-
tacts 106. The photo-resist and excess Fe is removed via a 
standard liftoff process making use of sonication in acetone. 
The CNTs are grown using catalyzed pyrolytic decomposi-
tion of hydrocarbon gases in a chemical vapor deposition 
chamber. In this case, the electrode array device 100 includes 
Fe catalyst particles between the pluralities of vertically 
aligned CNTs and the electrical contacts 106. 
It is also possible forthe Fe catalyst particles to serve as the 
electrical contacts 106. In these situations, the Si02 film of the 
substrate 102 is only patterned once. This pattern corresponds 
to the locations of the Fe catalyst layer to be grown. Afterthe 
CNTs are grown on the Fe catalyst particles, the electrical 
leads are fabricated. These can be made by selectively plating 
US 8,774,890 B2 
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portions of the substrate 102 corresponding to the leads them-
selves. Alternatively, electrical leads, in the form of nanow-
ires or other like structure, can be deposited directly on the 
substrate 102. 
10 
otides, amino acids, peptides, proteins, carbohydrates, lec-
tins, lipids, fats, fatty acids, viruses, antigens, immunogens, 
antibodies and fragments thereof, sera, immune stimulants, 
immune suppressors, sympathomimetics, xanthine deriva-
tives, cardiovascular agents, potassium channel blockers, cal-
cium channel blockers, beta-blockers, alpha-blockers, antiar-
rhythmics, antihypertensives, diuretics, antidiuretics, 
vasodilators comprising general, coronary, peripheral, or 
cerebral, central nervous system stimulants, vasoconstrictors, 
The CNTs can be functionalized, for example, by dipping 
them in a solution of the functionalizing agent. If there is 
concern about damage to the other components of the elec-
trode array device, then an additional photoresist layer can be 
created and removed to protect the other components during 
the functionalization step. 
Once the probes 104, electrical contacts 106 and electrical 
leads are prepared on the substrate 102, the optional process-
ing component 108 can be connected to the electrical leads. 
Another improved electrode array device, according to 
some embodiments of the present invention, is shown in FIG. 
2 and is generally designated by reference numeral 200. The 
electrode array device 200 comprises a substrate 202, a plu-
rality of probes 204, and an optional processing component 
208 exactly as described above for the electrode array device 
100 of FIG. 1. Probes 204 are identical to probes 104 of the 
electrode array device 100 of FIG. 1, with the exception that 
they are not electrically insulated from one another. Thus, 
electrode array device 200 is designed to provide a uniform 
stimulus and/or to take a single measurement across the entire 
electrode array device 200. 
10 gases, growth factors, growth inhibitors, hormones, estradiol, 
steroids, progesterone and derivatives thereof, testosterone 
and derivatives thereof, corticosteroids, angiogenic agents, 
antiangeogenic agents, hypnotics, immunosuppressives, 
muscle relaxants, parasympatholytics, psychostimulants, 
15 sedatives, tranquilizers, ionized and non-ionized active 
agents, anti-fungal agents, metals, small molecules, pharma-
ceuticals, hemotherapeutic agents, herbicides, fertilizers, 
wound healing agents, indicators of change in the bio-envi-
ronment, enzymes, nutrients, vitamins, minerals, coagulation 
20 factors, neurochemicals, cellular receptors, radioactive mate-
rials, cells, chemical or biological materials or compounds 
that induce a desired biological or pharmacological effect; 
and combinations thereof. 
The active agent delivery device 300 includes a substrate 
25 302 having an (i.e., at least one) aperture therein. The aperture 
is configured to allow an active agent to pass therethrough. 
Within the active agent delivery device 300, there is no limi-
tation on the composition or material from which the sub-
strate 102 is formed. 
Since the plurality of probes 204 are not electrically insu-
lated from one another, the substrate 202 does not need to be 
formed from an insulating material. When the substrate 202 is 
formed from a conductive material, it can be in electrical 
communication with the optional processing component 208. 30 
If, however, the substrate 202 is formed from an insulating 
material, then the electrode array device 200 can further 
include an optional electronic contact 206. In these situations, 
which is shown in FIG. 2, the optional electronic contact can 
be in electrical communication with the optional processing 35 
component 208. 
The electrode array device 200 of FIG. 2 can be fabricated 
exactly as described forthe electrode array device 100 of FIG. 
1, with the exception that a single electronic contact 206 can 
be prepared (if necessary) instead of a plurality of electrical 40 
contacts 106. If these are not needed, then the probes 204 can 
be disposed directly on the substrate 202. 
Again, this type of electrode array device 200 is beneficial 
in situations where a single measurement and/or a uniform 
level of electric stimulation is desired. It should, however, be 45 
understood to those skilled in the art to which this disclosure 
pertains that an electrode array device can be prepared where 
The active agent delivery device 300 also includes an active 
agent delivery member 304 disposed on a surface of the 
substrate 302. The active agent delivery member 304 also 
includes an aperture that projects in a direction perpendicular 
to the surface of the substrate 302 on which the active agent 
delivery member 304 is disposed. The aperture of the active 
agent delivery member 304 and the aperture of the substrate 
302 are substantially coaxial. That is, within a range of about 
10 percent variation, the center of the aperture in the active 
agent delivery member 304 is coaxial with the center of the 
aperture in the substrate 302. 
The aperture of the active agent delivery member 304 can 
be different in size from the aperture of the substrate 302, with 
the provision that the size of the aperture in the substrate 302 
must be less than or equal to the size of the aperture in the 
active agent delivery member 304. When more than one aper-
ture exists in each component, the apertures can be different 
in size within the individual component through which they 
extend. Further, a single aperture can have a non-uniform size 
along the length of that aperture. For example, the apertures 
a portion of the probes are electrically insulated from one 
another while another portion of the probes are not electri-
cally insulated from one another. This hybrid-type electrical 
array device, while encompassed by the various embodi-
ments of the present invention, is not illustrated in order to 
minimize redundancy. Specifically, such a device can be illus-
trated by merging the devices of FIGS. 1and2. 
50 within the substrate 302 optionally can be tapered such that 
the apertures are larger at the top (i.e., the surface on which 
the active agent delivery member 304 is disposed) surface 
than at the bottom surface. 
An improved active agent delivery device, according to 55 
some embodiments of the present invention, is shown in FIG. 
3 and is generally designated by reference numeral 300. As 
used herein, the term "active agent" can include, without 
limitation, agents for gene therapy, analgesics, antiarthritics, 
antiasthmatic agents, anticholinergics, anticonvulsants, anti- 60 
depressants, antidiabetic agents, antidiarrheals, anesthetics, 
antibiotics, antigens, antihistamines, anti-infectives, anti-in-
flammatory agents, antimicrobial agents, antimigraine prepa-
rations, antinauseants, antineoplastics, antiparkinsonism 
drugs, antipruritics, antipsychotics, antipyretics, antispas- 65 
modics, anorexics, antihelminthics, antiviral agents, nucleic 
acids, DNA, RNA, polynucleotides, nucleosides, nucle-
There is no particular limit to the shape of the apertures of 
the substrate 302 and/or the active agent delivery members 
304. For example, an aperture can have the shape of a circle, 
triangle, square, rectangle, pentagon, a cross, a star, a torus or 
donut, any other polygon whether solid or hollow (e.g., like a 
donut), or any other shape. 
The active agent delivery member 304 comprises a plural-
ity of vertically aligned CNTs that project away from the 
substrate 302. The active agent delivery member 304 can be 
directly or indirectly (i.e., via an intermediate layer of mate-
rial) connected to the substrate 302. The CNTs that are used to 
make the active agent delivery member 304 can be any type of 
carbon nanotube, as described above for the electrode array 
device 100 of FIG. 1. 
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There is no particular limitation on the shape of the active 
agent delivery member 304. When more than one active agent 
delivery member 304 is used, they can be identical to one 
another, or can have different shapes. Thus, the plurality of 
vertically aligned CNTs of an active agent delivery member 
3 04 can have the shape of a circle, triangle, square, rectangle, 
pentagon, a cross, a star, a torus or donut, any other polygon 
whether solid or hollow (e.g., like donut), or any other shape. 
There is no particular limitation on the height of the CNTs 
of the active agent delivery member 3 04. When more than one 
active agent delivery member 304 is used, they can have 
identical heights, or they can have different heights. For 
example, it may desirable to have active agent delivery mem-
bers 304 of different heights so that each active agent delivery 
member 304 can deliver the active agent to not only different 
lateral areas but different depths within the bio-environment 
in which the active agent delivery device 300 is implanted for 
in vivo applications (or to which the active agent delivery 
device 300 is contacted for in vitro applications). 
When the pressure necessary to penetrate into a particular 
type of tissue is high, the CNTs can be arranged to provide the 
active agent delivery member 304 with a quality of "sharp-
ness." This feature is described above with respect to the 
electrode array device 100 of FIG. 1. Similarly, other features 
of the active agent delivery members 304, including their 
longest lateral cross-sectional dimension, minimum spacing 
between individual active agent delivery members 304, and 
their number are similar to those for the probes 104 of elec-
trode array device 100 of FIG. 1. 
12 
member 304 to provide the active agent delivery device 300 
with all of the functionality of the electrode array device 100 
of FIG. 1. In such embodiments, the overall device 300 is a 
combined active agent delivery device and an electrode array 
device. This can be accomplished by implementing electrical 
contacts 306, similar to those described above for the elec-
trode array device 100 of FIG. 1. 
During operation of active agent delivery device 300, the 
active agent delivery device 300 is implanted in, or contacted 
10 
with, the bio-environment ofinterest. As desired, the process-
ing component 308 can activate the mechanism for regulating 
flow or delivery of the active agent of the active agent cham-
ber 310. Once the active agent is released from the active 
15 agent chamber 310, it will flow through the aperture in the 
substrate 302 towards the active agent delivery member 304. 
If the processing component 308 is in electrical communica-
tion with the active agent delivery member 304 (e.g., via an 
electronic contact 306), a bias voltage can be applied to the 
20 electronic contact 306 to expedite the flow of the active agent 
towards the active agent delivery member 304. Upon exiting 
the aperture of the substrate 302, the active agent can flow 
through the aperture of the active agent delivery member 304 
to the specific area of the bio-environment in/to which the 
25 active agent delivery device 300 is implanted/contacted. 
In embodiments where the active agent delivery device 300 
includes all of the features of the electrode array device 100 of 
FIG.1 (or the electrode array device 200 of FIG. 2), the active 
agent delivery device 300 also can be used measure and/or 
30 stimulate electrical activity in the particular bio-environment. On the bottom surface (i.e., the surface opposite the one on 
which the active agent delivery member 304 is disposed) of 
the substrate 302, there is disposed an active agent chamber 
310. The active agent chamber 310 can be any device or vessel 
that can be used to contain an active agent composition. The 
active agent chamber 310 includes a mechanism for regulat- 35 
ing flow of the active agent from the active agent chamber 310 
into the aperture(s) of the substrate 302 (and, by extension, 
into the aperture of the active agent delivery member 304). By 
way of example, the active agent chamber 310 can be a 
syringe comprising a piston and a barrel, wherein the mecha-
nism for regulating flow or delivery of the active agent into the 
aperture of the substrate 302 is movement of the piston. 
Another active agent chamber 310 is a bottle (or other like 
container), wherein the mechanism for regulating flow or 
delivery of the active agent into the aperture of the substrate 45 
302 is a mechanical pump. Other active agent chambers 310 
can be used as would be understood by those skilled in the art 
In this manner, if a specific condition is detected, an appro-
priate active agent can be introduced to the bio-environment. 
The delivery of the active agent can also be accompanied by 
stimulation of the bio-environment. 
An advantage of using a plurality of vertically aligned 
CNTs as the active agent delivery member 304 for the active 
agent delivery device 300 is that the active agent can be 
delivered to a larger area of the bio-environment than with 
existing devices. Specifically, rather than having all of the 
40 active agent be delivered to the bio-environment at the end of 
the active agent delivery member 304, the active agent can be 
delivered through gaps in the vertically aligned CNTs. Thus, 
the active agent can be delivered along the entire length of the 
active agent delivery member 304. 
The active agent delivery device 300 can be fabricated by 
first providing a substrate 302 active agent delivery member 
304 can be disposed. An aperture can be fabricated in the 
substrate 302. The aperture in the substrate 302 can be created 
by removing portions of the already-fabricated substrate 302, 
to which this disclosure pertains. 
The active agent delivery device 300 can further include an 
(i.e., at least one) optional processing component or unit 308. 
The optional processing component 308 is identical to the 
processing component 108 described for the electrode array 
device of FIG. 1, with the exception that it is configured to 
regulate the delivery of the active agent from the active agent 
chamber 310 to the aperture of the substrate 302. 
The processing component 308 optionally can also be in 
electrical communication with the active agent delivery 
member 304 so as to facilitate delivery of the active agent. For 
example, a bias potential can be applied to the active agent 
delivery member 304 so as to induce a pumping mechanism 
for delivering the active agent to the desired location. That is, 
through an electrostatic attraction forthe charged CNTs of the 
active agent delivery member 304, the rate at which the active 
agent travels through the aperture in the substrate 302 can be 
expedited. 
Alternatively, the processing component 308 can be in 
electrical communication with the active agent delivery 
50 or it can be created by intentionally leaving a void in specified 
locations during fabrication of the substrate 302. Removal of 
portions of the substrate 302 can be achieved, for example, by 
micro-machining, chemical or physical etching, photolitho-
55 
graphic techniques, or the like. 
Next, if desired, the optional electrical contact 306 can be 
disposed on the substrate 302. This can be accomplished 
using any known technique for doing so. For example, the 
electrical contact 306 can be pre-fabricated, and can be fas-
tened (e.g., mechanically or chemically) to the substrate 302. 
60 Alternatively, the electrical contact 306 can be fabricated 
directly on the substrate 302 using any known fabrication 
technique. Examples of such techniques are described above 
for the electrical contacts 106 of the electrode array device 
100 of FIG. 1, with the exception that the electrical contact 
65 306 will have an aperture therethrough. 
Additionally, mechanisms for rendering the electrical con-
tact 106 in electrical communication with the processing 
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component 108 can also be implemented, similar to what was 
described above for the electrode array device 100 of FIG. 1. 
After the optional electrical contact 306 has been disposed 
on the substrate 302, the plurality of vertically aligned CNTs 
can be created on the electrical contact 306. The fabrication, 
properties, and post-fabrication treatments of the CNTs of the 
active agent delivery member 304 are identical to what was 
described above for the electrode array device 100 of FIG. 1. 
After the CNTs have been disposed on the electrical con-
tact 306, the active agent chamber 310 can be coupled to the 
substrate 302.Alternatively, this can be done before any of the 
other steps (if desired). 
Finally, the optional processing component 308 can be 
coupled to the active agent chamber 310 and/or the active 
agent delivery member 304 (via the electrical contact 306). 
The active agent delivery device 300 is then complete and is 
ready for use. 
By way of example, one process for preparing an active 
agent delivery device 300 involves first providing a silicon 
wafer as the substrate 302. A thin film of Si02 is thermally 
grown on the top side of the substrate 302. An inductively 
coupled plasma reactive ion etching (ICP/RIE) instrument is 
used to prepare a plurality of apertures in the bottom side of 
the silicon wafer. The ICP/RIE instrument only etches the 
wafer and does not etch the Si02 film. The use of ICP/RIE 
allows for significantly thicker silicon wafers to be used as the 
substrate 302. For example, wafers having thicknesses of 
greater than or equal to about 250 micrometers can be used. 
This provides the advantage of greater mechanical stability 
for the active agent delivery devices 300 of the present inven-
tion. 
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402, an active agent delivery member 404, and an optional 
electrical contact 406 and processing component 408 exactly 
as described above for the active agent delivery device 300 of 
FIG. 3. The active agent chamber 410 is identical to the active 
agent chamber 310 of the active agent delivery device 300 of 
FIG. 3, with the exception that there is one active agent 
chamber 410 for each aperture in the substrate 402 (and, by 
extension, each an active agent delivery member 404). 
The active agent delivery device 400 of FIG. 4 can be 
10 fabricated exactly as described for the active agent delivery 
device 300 of FIG. 3, with the exception that, instead of 
coupling a single active agent chamber 410 to all of the 
apertures in the substrate 402, each aperture in the substrate 
402 is coupled to a separate active agent chamber 410. In 
15 addition, each active agent chamber 410 independently can 
be coupled to the processing component 408. 
The electrode array devices 100 and 200 and the active 
agent delivery devices 300 and 400 disclosed herein are 
capable of being used in a variety of applications. For 
20 example, the electrode array devices 100 and 200 can be 
implemented as neural probes, cochlear implants, retinal 
implants, spinal cord implants, and the like. The use of ver-
tically aligned CNTs as probes results in a size reduction, in 
some cases, of over 1000-fold compared to existing electrode 
25 array devices. In addition, in contrast to existing electrode 
array devices, the electrode array devices 100 and 200 
described herein do not require a structure-providing compo-
sition or material to encapsulate the CNTs. Similarly, appli-
cation of the active agent delivery devices 300 and 400 are 
30 equally limitless. 
The top surface of the substrate 302 (i.e., the one contain-
ing the Si02 film) is then patterned with a photoresist using 
photolithography. The pattern corresponds to the locations of 
the pluralities of CNTs to be grown. The pattern allow for a 35 
line-of-sight deposition path for the deposition of an Fe cata-
lyst layer directly on the Si02 film (and the photoresist). 
The various embodiments of the present invention are fur-
ther illustrated by the following non-limiting examples. 
EXAMPLES 
Example 1 
The photoresist and excess Fe is removed via a standard 
liftoff process making use of sonication in acetone. The top 
surface of the substrate 302, including the remaining Fe par- 40 
ticles, is patterned with a second photoresist using photoli-
thography. The remaining un-etched portions of the apertures 
in the substrate are etched using anICP/RIE instrument. Next, 
the second photoresist is removed. 
The CNTs are grown using catalyzed pyrolytic decompo- 45 
sition of hydrocarbon gases in a chemical vapor deposition 
chamber. In this case, the active agent delivery device 300 
includes Fe catalyst particles between the pluralities of ver-
tically aligned CNTs and the substrate 302. 
In applications where electrical contacts 306 are desired, 50 
the Fe catalyst particles can serve as the electrical contacts 
306. 
Fabrication of Electrode Array Devices 
A thin film of Si02 was thermally grown on the top side of 
a silicon wafer. The top surface was then patterned with a 
photoresist using photolithography. The pattern corre-
sponded to the locations of the CNTs to be grown. The pat-
tern's apertures allowed for a line-of-sight deposition path for 
the deposition of an iron (Fe) catalyst layer directly on the 
Si02 film of the wafer. The photo-resist and excess Fe was 
removed via a standard liftoff process making use of sonica-
tion in acetone. 
Vertically aligned CNT arrays composed of multi-walled 
carbon nanotubes (MWNTs) were grown via iron-catalyzed 
pyrolytic decomposition of hydrocarbon gases in a chemical 
vapor deposition (CVD) furnace. These samples were grown 
using a process in which the temperature in the chamber was 
ramped to 820 degrees Celsius (° C.) for 12 minutes under 
The CNTs can be functionalized, for example, by dipping 
them in a solution of the functionalizing agent. If there is 
concern about damage to the other components of the elec-
trode array device, then an additional photoresist layer can be 
created and removed to protect the other components during 
the functionalization step. 
The bottom side of the wafer substrate 302 is glued to a 
flat-edged syringe, which serves as the active agent chamber 
310. 
55 1000 standard cubic centimeters (seem) of argon gas, fol-
lowed by a 30 minute soak with 500 seem H2 , 1000 seem 
CH4 , and 120 seem acetylene, a 10 minute cool down period 
under 1000 seem argon, and a cool to room temperature under 
no gas flow. A representative scanning electron microscope 
At this time, the optional processing component 308 can be 
connected to the syringe and/or the electrical contacts 306. 
Another improved active agent delivery device, according 
to some embodiments of the present invention, is shown in 
FIG. 4 and is generally designated by reference numeral 400. 
The active agent delivery device 400 comprises a substrate 
60 (SEM) image of square-shaped CNT-containing electrode 
arrays is shown in FIG. 5. 
Some of the samples were functionalized with poly-L-
lysine, laminin-1 or a combination of both. Approximately 50 
microliters of the functionalizing composition were placed on 
65 the substrate surface for about 2 hours. The substrate was then 
washed with a phosphate buffer solution (PBS) and allowed 
to dry overnight. For the combined poly-L-lysine and lami-
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nin-1 functionalization of the CNTs, laminin-1 was first 
placed on the substrate surface for about 2 hours. The sample 
was then washed with PBS, and then coated with poly-L-
lysine for about 2 hours. The substrate was washed with PBS, 
and then allowed to dry overnight. 
The functionalized CNTs were more densely packed after 
functionalization. That is, while the untreated CNTs appeared 
to have the same density as when deposited on the substrate, 
the functionalized CNTs appeared bundled together. Thus, 
functionalization can be implemented to provide the CNT 
10 probes with greater mechanical strength and density. 
Example 2 
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wafer to make a series of holes with slightly different diam-
eters through the wafer, but not through the Si02 film. About 
40 holes were spaced approximately 677 micrometers apart 
in they-direction and about 2,102 micrometers apart in the 
x-direction. The diameter of the holes varied slightly between 
about 60 and about 70 micrometers, with an average diameter 
of 65 micrometers. 
The surface of the wafer containing the Si02 film was then 
patterned with a photoresist using photo lithography. The pat-
tern corresponded to the locations of the CNTs to be grown. 
The pattern's apertures allowed for a line-of-sight deposition 
path for the deposition of an iron (Fe) catalyst layer directly 
on the Si02 film of the wafer. The photo-resist and excess Fe 
was removed via a standard liftoff process making use of Characterization of the Electrode Array Devices 
15 sonication in acetone. 
In order to test the mechanical compatibility of the elec-
trode array devices of EXAMPLE 1 with brain tissue, a 0.6% 
agarose gel was made with an assumed stiffness of about 12 
kilopascals (kPa), which corresponds to the stiffness of the 
brain. To make this gel, SeaPrep agarose gel was mixed with 
lxPBS under constant heat. About 2 milliliters (mL) of the 
resulting solution was placed in several petri dishes, which 
were refrigerated and allowed to solidify overnight. 
Once the gels solidified, a CNT array was pushed into the 
surface of each gel for about 1 minute, and was left implanted 
in the gel overnight. The CNT array was then removed from 
the gel and imaged via SEM to determine ifthe CNTs were 
still intact. 
The top surface of the substrate, including the Fe particles, 
was patterned with a second photoresist using photolithogra-
phy. The remaining un-etched portions of the apertures in the 
substrate were then etched using an ICP/RIE instrument. 
20 Next, the second photoresist was removed. The SEM image 
of FIG. 9(a) reveals a representative aperture in the wafer 
prior to CNT growth. 
The CNTs were grown using catalyzed pyrolytic decom-
position of hydrocarbon gases in a chemical vapor deposition 
25 chamber, similar to what was described in EXAMPLE 1. An 
SEM image of a representative active agent delivery member 
is shown in FIG. 9(b). 
Next, the back side of the substrate (i.e., the side opposite 
the CNTs) was coupled with a syringe barrel. 
The embodiments of the present invention are not limited 
to the particular formulations, process steps, and materials 
disclosed herein as such formulations, process steps, and 
materials may vary somewhat. Moreover, the terminology 
employed herein is used for the purpose of describing exem-
SEM images of the non-functionalized and functionalized 
CNT arrays, after removal from the gels, are provided in 
FIGS. 6-7. Specifically, FIG. 6(a) is a representative SEM 30 
image of a non-functionalized array of CNT electrodes after 
about 18 to about 24 hours of implantation in a gel. Observa-
tion at higher magnifications, as shown in the SEM image of 
FIG. 6(b), reveals that the nodes are reduced only minimally 
35 plary embodiments only and the terminology is not intended 
to be limiting since the scope of the various embodiments of 
the present invention will be limited only by the appended 
claims and equivalents thereof. 
in vertical height. The untreated (i.e., non-functionalized) 
CNT electrodes were somewhat distorted in shape after 
implantation, but their mechanical stability and their connec-
tion to the substrate remained intact. 
Therefore, while embodiments of this disclosure have been The SEM image of FIG. 7 illustrates a group of probes that 
were functionalized by both poly-L-lysine and laminin-1, 
after implantation in the gel. Some of the probes in the array 
remained vertical, while some of the probes were bent. For 
the most part, the probes were significantly decreased in cross 
sectional area, which may have been a function of the densi-
fication by functionalization and/or some damage to the 
CNTs in the inner region of the probes. 
40 described in detail with particular reference to exemplary 
embodiments, those skilled in the art will understand that 
variations and modifications can be effected within the scope 
of the disclosure as defined in the appended claims. Accord-
ingly, the scope of the various embodiments of the present 
45 invention should not be limited to the above-discussed 
embodiments, and should only be defined by the following 
claims and all equivalents. After removal from the gels, probes that were functional-ized by poly-L-lysine had their overall structure remain 
intact. That is, the original vertical height and stability were 
retained. These results were observed uniformly across the 
surface of the substrate by SEM. Of the different functional- 50 
izing agents, poly-L-lysine-functionalized CNT arrays 
retained the greatest mechanical stability. 
In addition to the mechanical studies, a cell adhesion study 
was performed. PC-12 cells were seeded onto the electrode 
arrays. Generally, the PC-12 cells attached to the CNT probes 55 
in each type of electrode array device. The samples where the 
CNTs were functionalized, however, had greater attachment 
of the PC-12 cells on the CNT arrays. A representative SEM 
image illustrating cell attachment between electrodes is 
shown in FIG. 8. 
Example 3 
Fabrication of an Active Agent Delivery Device 
A thin film of Si02 was thermally grown on the top side of 
a silicon wafer. An ICP/RIE instrument was used on a silicon 
60 
65 
All patents and other references cited herein are incorpo-
rated by reference as if fully set forth herein. 
What is claimed is: 
1. An electrode array device, comprising: 
a substrate having an aperture therein; and 
a plurality of probes disposed on the substrate, wherein 
each probe of the plurality of probes comprises a plural-
ity of aligned carbon nanotubes, wherein the plurality of 
aligned carbon nanotubes are not encapsulated by a 
structure-providing material, and wherein there is a gra-
dient in a height of the carbon nanotubes such that each 
probe of the plurality of probes has a saw-toothed pro-
file. 
2. The electrode array device of claim 1, further comprising 
a plurality of electrical contacts, each of which are indepen-
dently disposed between a probe of the plurality of probes and 
the substrate. 
3. The electrode array device of claim 1, further comprising 
a processing component in electrical communication with at 
least one probe of the plurality of probes. 
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4. The electrode array device of claim 1, wherein each 
probe of the plurality of probes is electrically isolated from 
one another. 
5. The electrode array device of claim 1, wherein the car-
bon nanotubes of each probe of the plurality of probes are 
functionalized to increase the density of the carbon nano-
tubes. 
6. The electrode array device of claim 5, wherein the car-
bon nanotubes of each probe of the plurality of probes are 
functionalized with poly-L-lysine. 
7. The electrode array device of claim 5, wherein the car-
bon nanotubes of each probe of the plurality of probes are 
functionalized with a laminin. 
8. An active agent delivery device, comprising: 
a substrate having an aperture therein; 
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through the aperture of the substrate, the aperture of the 
active agent delivery member, and gaps between the 
aligned carbon nanotubes. 
10. The active agent delivery device of claim 9, further 
comprising a processing component in electrical communi-
cation with the active agent chamber. 
11. The active agent delivery device of claim 9, further 
comprising a processing component in electrical communi-
cation with the active agent delivery member. 
12. The active agent delivery device of claim 9, further 
comprising an electrical contact, disposed between at least a 
portion of the active agent delivery member and at least a 
portion of the substrate. 
13. The active agent delivery device of claim 9, wherein the 
plurality of aligned carbon nanotubes are functionalized to 
increase the density of the carbon nanotubes. 
an active agent delivery member disposed on a surface of 
the substrate and having an aperture therein, wherein the 
ac.tive agent delivery member comprises a plurality of 
aligned carbon nanotubes, wherein the plurality of 
aligned carbon nanotubes are not encapsulated by a 
structure-providing material, wherein there is a gradient 
14. The active agent delivery device of claim 9, wherein the 
plurality of aligned carbon nanotubes are functionalized with 
20 poly-L-lysine. 
15. The active agent delivery device of claim 9, wherein the 
plurality of aligned carbon nanotubes are functionalized with 
alaminin. 
in a height of the carbon nanotubes such that the active 
delivery agent member has a saw-toothed profile, and 
wherein the aperture of the active agent delivery member 
and the aperture of the substrate are substantially 25 
coaxial; and 
means for delivering an active agent through the aperture of 
the substrate, the aperture of the active agent delivery 
member, and gaps between the aligned carbon nano-
tubes. 
9. An active agent delivery device, comprising: 
a substrate having an aperture therein; 
an active agent delivery member disposed on a first surface 
30 
of the substrate and having an aperture therein, wherein 
the active agent delivery member comprises a plurality 35 
of aligned carbon nanotubes, wherein the plurality of 
aligned carbon nanotubes are not encapsulated by a 
structure-providing material, wherein there is a gradient 
in a height of the carbon nanotubes such that the active 
delivery agent member has a saw-toothed profile, and 40 
wherein the aperture of the active agent delivery member 
and the aperture of the substrate are substantially 
coaxial; and 
an active agent chamber disposed on a second surface of 
the substrate configured to deliver an active agent 
16. An active agent delivery device, comprising: 
a substrate having a plurality of apertures therein; 
a plurality of active agent delivery members disposed on a 
first surface of the substrate, wherein each active agent 
delivery member of the plurality of active agent delivery 
members has an aperture therein, wherein each active 
age.nt delivery member of the plurality of active agent 
delivery members comprises a plurality of aligned car-
bon nanotubes, wherein the plurality of aligned carbon 
nanotubes are not encapsulated by a structure-providing 
material, wherein there is a gradient in a height of the 
carbon nanotubes such that the active delivery agent 
member has a saw-toothed profile, and wherein each 
aperture of an active agent delivery member is substan-
tially coaxial with an aperture of the substrate; and 
an active agent chamber disposed on a second surface of 
the substrate configured to deliver an active agent 
through at least one aperture of the substrate, at least one 
active agent delivery member aperture, and gaps 
between the aligned carbon nanotubes of at least one 
active agent delivery member. 
* * * * * 
